Ergoteles’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Ergoteles’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18,105	Closed	-$13K	–	1956
2022 Q4	$13K	Buy	+18,105	New	+$17.9K	﹤0.01%	1363

Other funds holding BLCM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ergoteles's BLCM Position: Q1 2023 in Review

Ergoteles sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2023, closing a stake of 18,105 shares — an estimated $13K sold.

Ergoteles first reported a position in BLCM in Q4 2022 and held it in 1 quarter. The position peaked at $13K in Q4 2022. 25 funds tracked by Wall St. Rank hold BLCM as of Q1 2023.

Ergoteles reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 18,105 Bellicum Pharmaceuticals, Inc. shares in Q1 2023, an estimated $13K.
Ergoteles first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2022 and held it in 1 quarter.
Ergoteles's Bellicum Pharmaceuticals, Inc. position peaked at $13K in Q4 2022.
25 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.